邮件订阅 RSS

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

影响特发性肺纤维化治疗和预后的常见合并症

李珊,  黄慧,  徐作军

downloadPDF
文章导航 > 协和医学杂志  > 2018 >  9(3): 251-255
李珊, 黄慧, 徐作军. 影响特发性肺纤维化治疗和预后的常见合并症[J]. 协和医学杂志, 2018, 9(3): 251-255. doi: 10.3969/j.issn.1674-9081.2018.03.012
引用本文: 李珊, 黄慧, 徐作军. 影响特发性肺纤维化治疗和预后的常见合并症[J]. 协和医学杂志, 2018, 9(3): 251-255. doi: 10.3969/j.issn.1674-9081.2018.03.012
shu
Shan LI, Hui HUANG, Zuo-jun XU. Common Comorbidities in Patients with Idiopathic Pulmonary Fibrosis[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(3): 251-255. doi: 10.3969/j.issn.1674-9081.2018.03.012
Citation: Shan LI, Hui HUANG, Zuo-jun XU. Common Comorbidities in Patients with Idiopathic Pulmonary Fibrosis[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(3): 251-255. doi: 10.3969/j.issn.1674-9081.2018.03.012
shu

影响特发性肺纤维化治疗和预后的常见合并症

doi: 10.3969/j.issn.1674-9081.2018.03.012

  • 中国医学科学院 北京协和医学院 北京协和医院呼吸内科, 北京 100730

基金项目: 

北京市自然科学基金项目 7162157

详细信息
    通讯作者:

    徐作军 电话:010-69155039, E-mail:xuzj@hotmail.com

  • 中图分类号: R563

Common Comorbidities in Patients with Idiopathic Pulmonary Fibrosis

  • Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

More Information

    摘要
  • 摘要: 特发性肺纤维化(idiopathic pulmonary fibrosis, IPF)是一种慢性进展性致纤维化性疾病, 预后极差。IPF以中老年男性多见, 容易出现多种临床合并症, 包括肺气肿、肺癌、心血管疾病等。存在合并症的IPF患者临床症状更多、预后更差。本文详细阐述影响特发性肺纤维化治疗和预后的常见合并症, 以期提高临床对于IPF合并症的认识和诊疗水平, 从而改善IPF患者的生活质量及预后。
    Abstract: Idiopathic pulmonary fibrosis(IPF) is a progressive fatal disease of the lung with unknown etiology and limited treatment options. It is more common in men and the elderly aged over 50 years, which also have a high incidence of emphysema, lung neoplasms, and cardiovascular disease. IPF patients with comorbidities often have a worse prognosis than those with IPF alone. We write this article in reference to common comorbidities in patients with idiopathic pulmonary fibrosis to draw physicians' attention. Clinical physicians should know that much can be done to identify and alleviate symptoms of those comorbidities, and to potentially improve the overall quality of life of these patients.
    • HTML全文
    • 参考文献(40)
  • [1] Karampitsakos T, Tzilas V, Tringidou R, et al. Lung cancer in patients with idiopathic pulmonary fibrosis[J]. Pulm Pharmacol Ther, 2017, 45:1-10. doi:  10.1016/j.pupt.2017.03.016
    [2] Tomassetti S, Gurioli C, Ryu JH, et al. The impact of lung cancer on survival of idiopathic pulmonary fibrosis[J]. Chest, 2015, 147:157-164. doi:  10.1378/chest.14-0359
    [3] Watanabe A, Higami T, Ohori S, et al. Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis?[J].J Thorac Cardiovasc Surg, 2008, 136:1357-1363. doi:  10.1016/j.jtcvs.2008.07.016
    [4] Ono T, Hareyama M, Nakamura T, et al. The clinical results of proton beam therapy in patients with idiopathic pulmonary fibrosis:a single center experience[J].Radiat Oncol, 2016, 11:56. doi:  10.1186/s13014-016-0637-3
    [5] Iwata T, Yoshida S, Nagato K, et al. Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis[J]. Surg Today, 2015, 45:1263-1270. doi:  10.1007/s00595-014-1071-5
    [6] Mediavilla-Varela M, Boateng K, Noyes D, et al. The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts[J].BMC Cancer, 2016, 16:176. doi:  10.1186/s12885-016-2162-z
    [7] Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1):a phase 3, double-blind, randomised controlled trial[J]. Lancet Oncol, 2014, 15:143-155. doi:  10.1016/S1470-2045(13)70586-2
    [8] Cottin V, Nunes H, Brillet PY, et al. Combined pulmonary fibrosis and emphysema:a distinct underrecognised entity[J]. Eur Respir J, 2005, 26:586-593. doi:  10.1183/09031936.05.00021005
    [9] Cottin V, Hansell DM, Sverzellati N, et al. Effect of emphysema extent on serial lung function in patients with idiopathic pulmonary fibrosis[J]. Am J Respir Crit Care Med, 2017, 196:1162-1171. doi:  10.1164/rccm.201612-2492OC
    [10] Sugino K, Ishida F, Kikuchi N, et al. Comparison of clinical characteristics and prognostic factors of combined pulmonary fibrosis and emphysema versus idiopathic pulmonary fibrosis alone[J]. Respirology, 2014, 19:239-245. doi:  10.1111/resp.12207
    [11] Kohashi Y, Arai T, Sugimoto C, et al. Clinical Impact of Emphysema Evaluated by High-Resolution Computed Tomography on Idiopathic Pulmonary Fibrosis Diagnosed by Surgical Lung Biopsy[J]. Respiration, 2016, 92:220-228. doi:  10.1159/000448118
    [12] Mejia M, Carrillo G, Rojas-Serrano J, et al. Idiopathic pulmonary fibrosis and emphysema:decreased survival associated with severe pulmonary arterial hypertension[J]. Chest, 2009, 136:10-15. doi:  10.1378/chest.08-2306
    [13] Dong F, Zhang Y, Chi F, et al. Clinical efficacy and safety of ICS/LABA in patients with combined idiopathic pulmonary fibrosis and emphysema[J]. Int J Clin Exp Med, 2015, 8:8617-8625. http://europepmc.org/articles/PMC4538025/
    [14] Raghu G, Amatto VC, Behr J, et al. Comorbidities in idiopathic pulmonary fibrosis patients:a systematic literature review[J]. Eur Respir J, 2015, 46:1113-1130. doi:  10.1183/13993003.02316-2014
    [15] Hayes D, Jr., Black SM, Tobias JD, et al. Influence of Pulmonary Hypertension on Patients With Idiopathic Pulmonary Fibrosis Awaiting Lung Transplantation[J]. Ann Thorac Surg, 2016, 101:246-252. doi:  10.1016/j.athoracsur.2015.06.024
    [16] Alkukhun L, Wang XF, Ahmed MK, et al. Non-invasive screening for pulmonary hypertension in idiopathic pulmonary fibrosis[J]. Respir Med, 2016, 117:65-72. doi:  10.1016/j.rmed.2016.06.001
    [17] Idiopathic Pulmonary Fibrosis Clinical Research N, Zisman DA, Schwarz M, et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis[J]. N Engl J Med, 2010, 363:620-628. doi:  10.1056/NEJMoa1002110
    [18] Han MK, Bach DS, Hagan PG, et al. Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction[J]. Chest, 2013, 143:1699-1708. doi:  10.1378/chest.12-1594
    [19] Mermigkis C, Bouloukaki I, Antoniou K, et al. Obstructive sleep apnea should be treated in patients with idiopathic pulmonary fibrosis[J]. Sleep Breath, 2015, 19:385-391. doi:  10.1007/s11325-014-1033-6
    [20] Gille T, Didier M, Boubaya M, et al. Obstructive sleep apnoea and related comorbidities in incident idiopathic pulmonary fibrosis[J]. Eur Respir J, 2017, 49:1601934. doi:  10.1183/13993003.01934-2016
    [21] Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement:idiopathic pulmonary fibrosis:evidence-based guidelines for diagnosis and management[J]. Am J Respir Crit Care Med, 2011, 183:788-824. doi:  10.1164/rccm.2009-040GL
    [22] Raghu G, Freudenberger TD, Yang S, et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis[J]. Eur Respir J, 2006, 27:136-142. doi:  10.1183/09031936.06.00037005
    [23] Lee JS, Song JW, Wolters PJ, et al. Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis[J]. Eur Respir J, 2012, 39:352-358. doi:  10.1183/09031936.00050911
    [24] Lee JS. The Role of Gastroesophageal Reflux and Microaspiration in Idiopathic Pulmonary Fibrosis[J]. Clin Pulm Med, 2014, 21:81-85. doi:  10.1097/CPM.0000000000000031
    [25] Lee JS, Collard HR, Anstrom KJ, et al. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis:an analysis of data from three randomised controlled trials[J]. Lancet Respir Med, 2013, 1:369-376. doi:  10.1016/S2213-2600(13)70105-X
    [26] Linden PA, Gilbert RJ, Yeap BY, et al. Laparoscopic fundoplication in patients with end-stage lung disease awaiting transplantation[J]. J Thorac Cardiovasc Surg, 2006, 131:438-446. doi:  10.1016/j.jtcvs.2005.10.014
    [27] Fulton BG, Ryerson CJ. Managing comorbidities in idiopathic pulmonary fibrosis[J]. Int J Gen Med, 2015, 8:309-318. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=Doaj000004008806
    [28] Sprunger DB, Olson AL, Huie TJ, et al. Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease[J]. Eur Respir J, 2012, 39:125-132. doi:  10.1183/09031936.00041411
    [29] Dalleywater W, Powell HA, Fogarty AW, et al. Venous thromboembolism in people with idiopathic pulmonary fibr-osis:a population-based study[J]. Eur Respir J, 2014, 44:1714-1715. doi:  10.1183/09031936.00099614
    [30] Nathan SD, Barnett SD, Urban BA, et al. Pulmonary embolism in idiopathic pulmonary fibrosis transplant recipients[J]. Chest, 2003, 123:1758-1763. doi:  10.1378/chest.123.5.1758
    [31] Noth I, Anstrom KJ, Calvert SB, et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis[J]. Am J Respir Crit Care Med, 2012, 186:88-95. doi:  10.1164/rccm.201202-0314OC
    [32] Rochwerg B, Raghu G. Reply:Can Warfarin Be Used in the Treatment of Pulmonary Embolism in Idiopathic Pulmonary Fibrosis?[J]. Am J Respir Crit Care Med, 2016, 193:811. doi:  10.1164/rccm.201601-0078LE
    [33] Hubbard RB, Smith C, Le JeuneI, et al. The association between idiopathic pulmonary fibrosis and vascular disease:a population-based study[J]. Am J Respir Crit Care Med, 2008, 178:1257-1261. doi:  10.1164/rccm.200805-725OC
    [34] Kim WY, Mok Y, Kim GW, et al. Association between idiopathic pulmonary fibrosis and coronary artery disease:a case-control study and cohort analysis[J]. Sarcoidosis Vasc Diffuse Lung Dis, 2015, 31:289-296. http://www.ncbi.nlm.nih.gov/pubmed/25591140
    [35] Nathan SD, Basavaraj A, Reichner C, et al. Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis[J]. Respir Med, 2010, 104:1035-1041. doi:  10.1016/j.rmed.2010.02.008
    [36] Nathan SD, Weir N, Shlobin OA, et al. The value of computed tomography scanning for the detection of coronary artery disease in patients with idiopathic pulmonary fibrosis[J]. Respirology, 2011, 16:481-486. doi:  10.1111/j.1440-1843.2010.01919.x
    [37] Nielsen TD, Bahnson T, Davis RD, et al. Atrial fibrillation after pulmonary transplant[J]. Chest, 2004, 126:496-500. doi:  10.1378/chest.126.2.496
    [38] Gribbin J, Hubbard R, Smith C. Role of diabetes mellitus and gastro-oesophageal reflux in the aetiology of idiopathic pulmonary fibrosis[J]. Respir Med, 2009, 103:927-931. doi:  10.1016/j.rmed.2008.11.001
    [39] Enomoto T, Usuki J, Azuma A, et al. Diabetes mellitus may increase risk for idiopathic pulmonary fibrosis[J]. Chest, 2003, 123:2007-2011. doi:  10.1378/chest.123.6.2007
    [40] Kim YJ, Park JW, Kyung SY, et al. Clinical characteristics of idiopathic pulmonary fibrosis patients with diabetes mellitus:the national survey in Korea from 2003 to 2007[J]. J Korean Med Sci, 2012, 27:756-760. doi:  10.3346/jkms.2012.27.7.756
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  280
  • HTML全文浏览量:  25
  • PDF下载量:  344
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-12-18
  • 刊出日期:  2018-05-30

目录

    /

    返回文章
    返回
    友情链接: 国家卫生健康委员会 北京协和医院 中国医学科学院 学术不端检测系统 国际知识资源总库 中国知网 术语在线 中国全科医学
    地址：北京市东城区帅府园1号 北京协和医院老楼7号楼
    3层302室 《协和医学杂志》编辑部
    电话：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    期刊网站版权所有：《协和医学杂志》编辑部
    京ICP备 11002662

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计

    x 关闭 永久关闭

    【温馨提醒】近日，《协和医学杂志》编辑部接到作者反映，有多名不法人员冒充期刊编辑发送见刊通知，鼓动作者添加微信，从而骗取版面费的行为。特提醒您，本刊与作者联系的方式均为邮件通知或电话，稿件进度通知邮箱为：mjpumch@126.com，编辑部电话为：010-69154261，请提高警惕，谨防上当受骗！如有任何疑问，请致电编辑部核实。谢谢！